8-K: Shuttle Pharma Issues Shares for Asset Purchase Payment

Shuttle Pharmaceuticals Holdings, Inc. amended an asset purchase agreement to accelerate a portion of its first installment payment through the issuance of 320,496 common shares.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. (Parent) and its wholly-owned subsidiary 1563868 B.C. Ltd. (Purchaser) entered into a First Amendment to an Asset Purchase Agreement with 1542770 BC Ltd. (Seller) and ZhiTian (Andy) Zhang (Seller Guarantor) on December 23, 2025.
• The amendment accelerates a portion of the First Installment Payment due under the original agreement dated November 20, 2025.
• Parent issued 320,496 shares of its Common Stock to the Seller on December 23, 2025, valued at $1.76 per share, totaling $564,072.96.
• This share issuance represents 19.99% of the issued and outstanding shares of Parent Common Stock as of the closing date of the original agreement.
• The remaining portion of the First Installment Payment, totaling $2,435,927.64, will be paid in cash on the 6-month anniversary of the Closing Date.
• The issuance of these shares was an unregistered sale of equity securities under Section 4(a)(2) and/or Rule 506(b) and Rule 903 of Regulation S.

Sentiment

Score: 5

Explanation: The filing describes a transactional amendment to an asset purchase agreement. While it involves equity dilution, it also represents an agreed-upon acceleration of a payment, which can be seen as a positive for the seller and potentially for the company in terms of structuring its liabilities. The overall impact is neutral without more context on the acquired assets and the company's strategic rationale.

Positives

• Accelerated settlement of a portion of the First Installment Payment, providing earlier liquidity for the seller.
• Reduced immediate cash outflow for the accelerated portion of the payment, conserving company cash resources.

Negatives

• Issuance of 320,496 new shares results in dilution for existing shareholders.
• The share issuance represents 19.99% of outstanding shares, which is a significant percentage of the company's equity.

Risks

• Potential for future dilution if additional shares are issued for the Second Installment Payment.
• Requirement for stockholder approval if future share payments exceed 19.99% of outstanding shares, which could introduce uncertainty or delays.
• The unregistered nature of the share sale may limit liquidity for the recipient (Seller).

Future Outlook

The company is committed to fulfilling the remaining payment obligations under the Asset Purchase Agreement, including a cash payment of $2,435,927.64 for the First Installment and a Second Installment Payment due on the one-year anniversary of the Closing Date, which may include additional equity issuance subject to stockholder approval if it exceeds 19.99% of outstanding shares.

Management Comments

• Christopher Cooper signed the report as Chief Executive Officer for Shuttle Pharmaceuticals Holdings, Inc. and as President for 1563868 B.C. Ltd.

Industry Context

This transaction reflects a common strategy in the biotechnology and pharmaceutical sectors where companies acquire assets, often intellectual property or development programs, to expand their pipeline. The use of equity as part of the consideration is also typical, allowing companies to conserve cash while leveraging their stock value. The 19.99% threshold for equity issuance without shareholder approval is a standard regulatory consideration to avoid triggering certain corporate governance requirements.

Comparison to Industry Standards

• N/A. The filing does not provide sufficient detail on the acquired assets or the specific terms of the original purchase agreement to allow for a meaningful comparison to specific comparable companies, projects, or industry benchmarks.

Corporate Governance

Related Party Transactions

• The Purchaser, 1563868 B.C. Ltd., is a wholly-owned subsidiary of Shuttle Pharmaceuticals Holdings, Inc.

Stakeholder Impact

• **Shareholders:** Experience dilution due to the issuance of 320,496 new common shares, representing 19.99% of outstanding shares.
• **Seller (1542770 BC Ltd.):** Received an accelerated portion of its payment in the form of company stock, providing earlier liquidity for that portion.
• **Company (Shuttle Pharmaceuticals Holdings, Inc.):** Manages its cash flow by using equity for a portion of the payment, while committing to future cash and potential equity payments.

Next Steps

• Payment of the remaining $2,435,927.64 cash portion of the First Installment Payment on the 6-month anniversary of the Closing Date.
• Payment of the Second Installment Payment on the one-year anniversary of the Closing Date, which may involve cash and/or Parent Common Stock.
• Potential requirement for stockholder approval if future equity issuances for installment payments exceed 19.99% of outstanding shares.

Key Dates

Recommendation

This filing details a transactional amendment to an asset purchase agreement, involving an equity issuance that results in dilution for existing shareholders. While it provides clarity on payment structure and conserves immediate cash, it does not offer new information on the company's operational performance, strategic direction, or the value of the acquired assets. Therefore, a 'hold' recommendation is appropriate as investors should await further details on the strategic impact of the acquired assets and future financial performance before making a definitive investment decision.

Keywords

Shuttle Pharmaceuticals, SHPH, Asset Purchase Agreement, Equity Issuance, Common Stock, SEC Filing, Form 8-K, Dilution, Unregistered Securities, Corporate Action